OBX.US Obsidian Therapeutics, Inc. Common Stock

Healthcare Biotechnology USA Stocks
12.56 USD
Close of Nov 15, 2026
9.60 49.97
Market cap
USD 776M
P/E
-
P/B
-
ROE
-40.0%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is OBX.US undervalued?

Graham number

The Graham number of Obsidian Therapeutics, Inc. Common Stock cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Obsidian Therapeutics, Inc. Common Stock fundamental analysis

No fundamental analysis for Obsidian Therapeutics, Inc. Common Stock yet.

Obsidian Therapeutics, Inc. Common Stock stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Obsidian Therapeutics, Inc. Common Stock

Obsidian Therapeutics, Inc. operates as a clinical-stage biotechnology company developing engineered cell and gene therapies. The company is developing investigational therapies, including OBX-115, which is being evaluated in clinical trials for advanced solid tumors, advanced melanoma, and relapsed refractory non-small cell lung cancer. It utilizes a proprietary Cytodriver technology platform designed to regulate protein function using FDA-approved small-molecule drugs and …

Full company profile